Precision Peptide orders 20,000 thymosin alpha-1 transdermal patches for launch
Each US-manufactured patch is formulated to deliver 2 mg of the immune-modulating peptide, the company says, following its earlier BPC-157 patch.
TR
By Tom Reyes · Markets Editor
Oct 8 15:20 ETSource: The Globe and Mail
The wire
- 01Pangea Natural Food's Precision Peptide Company ordered a first commercial run of 20,000 needle-free thymosin alpha-1 patches, each formulated at 2 mg, ahead of a planned US launch.
- 02It is the firm's second peptide patch to move from testing to commercial scale after BPC-157, and signals continued direct-to-consumer positioning for wellness-channel peptides.
- 03The announcement covers manufacturing volume only; no clinical data, transdermal absorption figures or regulatory status were disclosed, and the company reports continuing losses and cash burn.
From the source
Read at theglobeandmail.comPrecision Peptide Orders First Commercial Run of Thymosin Alpha-1 Patch
Pangea Natural Food, Inc. ( (TSE:BPC) ) has issued an announcement.
